Wang Jianjun, Chen Xi, Qin Chuan, Shi Ruizi, Huang Yu, Gong Jianping, Zeng Xintao, Wang Decai
Department of Hepatobiliary Surgery, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, China.
NHC Key Laboratory of Nuclear Technology Medical Transformation, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, China.
BMC Infect Dis. 2025 Feb 14;25(1):223. doi: 10.1186/s12879-025-10601-6.
Patients with liver cirrhosis face high infection risks due to immune dysfunction and hospital-related factors, increasing mortality rates when sepsis occurs. While various biomarkers predict outcomes in cirrhosis, few are accessible and reliable. This study addresses the gap by evaluating the prognostic potential of the lactate-to-albumin ratio (LAR).
We retrospectively analyzed data from patients with cirrhosis and sepsis who were admitted to the intensive care unit at Beth Israel Deaconess Medical Center between 2008 and 2022. LAR was calculated from the ratio obtained from the first measurement taken within 24 h of admission. The optimal LAR threshold was determined using R statistical software. Kaplan-Meier analysis was used to compare mortality risks between two patient groups, while multivariate Cox proportional hazards regression models were used to assess the association between LAR and mortality risk in patients with cirrhosis and concomitant sepsis. A restricted cubic spline (RCS) was used to explore potential dose-response relationships between LAR and mortality. Receiver operating characteristic (ROC) analyses were used to assess the predictive ability, sensitivity, and specificity of LAR for all-cause mortality in patients with cirrhosis and combined sepsis, and the area under the curve (AUC) was calculated. Finally, subgroup analyses were performed to assess the relationship between LAR and prognosis across different populations.
A total of 1731 patients were included in the study. The optimal LAR threshold was identified as 1.0 using R statistical software. Kaplan-Meier analysis indicated that patients with higher LAR levels had a higher risk of 14-day, 28-day, and 90-day all-cause mortality (all log-rank P < 0.001). Multivariate Cox proportional hazards models indicated independent associations between higher LAR levels and all-cause mortality at 14-day, 28-day, and 90-day before and after adjusting for confounders. RCS analysis revealed a nonlinear association between LAR and short- and long-term all-cause mortality in patients with cirrhosis and sepsis. ROC curve analysis showed that although the predictive value of LAR for the prognosis of patients with cirrhosis combined with sepsis was slightly inferior to that of the Model for End-Stage Liver Disease score, it was significantly better than that of lactate, albumin, and the Sequential Organ Failure Assessment. Subgroup analyses showed no significant interactions between LAR and any specific subgroup.
LAR has good predictive value for the prognosis of patients with cirrhosis and sepsis.
肝硬化患者由于免疫功能障碍和医院相关因素面临较高的感染风险,发生脓毒症时死亡率会增加。虽然各种生物标志物可预测肝硬化的预后,但很少有易于获取且可靠的。本研究通过评估乳酸与白蛋白比值(LAR)的预后潜力来填补这一空白。
我们回顾性分析了2008年至2022年期间入住贝斯以色列女执事医疗中心重症监护病房的肝硬化合并脓毒症患者的数据。LAR由入院后24小时内首次测量所得的比值计算得出。使用R统计软件确定最佳LAR阈值。采用Kaplan-Meier分析比较两组患者的死亡风险,同时使用多变量Cox比例风险回归模型评估LAR与肝硬化合并脓毒症患者死亡风险之间的关联。使用受限立方样条(RCS)来探索LAR与死亡率之间潜在的剂量反应关系。采用受试者工作特征(ROC)分析评估LAR对肝硬化合并脓毒症患者全因死亡率的预测能力、敏感性和特异性,并计算曲线下面积(AUC)。最后,进行亚组分析以评估LAR与不同人群预后之间的关系。
本研究共纳入1731例患者。使用R统计软件确定最佳LAR阈值为1.0。Kaplan-Meier分析表明,LAR水平较高的患者14天、28天和90天全因死亡风险更高(所有对数秩检验P < 0.001)。多变量Cox比例风险模型表明,在调整混杂因素前后,较高的LAR水平与14天、28天和90天的全因死亡率之间存在独立关联。RCS分析显示,LAR与肝硬化合并脓毒症患者的短期和长期全因死亡率之间存在非线性关联。ROC曲线分析表明,虽然LAR对肝硬化合并脓毒症患者预后的预测价值略低于终末期肝病模型评分,但明显优于乳酸、白蛋白和序贯器官衰竭评估。亚组分析显示LAR与任何特定亚组之间均无显著交互作用。
LAR对肝硬化合并脓毒症患者的预后具有良好的预测价值。